Imperial College London Featured PhD Programmes
Xi’an Jiaotong-Liverpool University Featured PhD Programmes
University of Hong Kong Featured PhD Programmes

Pharmacology / Toxicology PhD Projects, Programs & Scholarships

We have 148 Pharmacology / Toxicology PhD Projects, Programs & Scholarships

Discipline

Discipline

Biological & Medical Sciences

Location

Location

All locations

Institution

Institution

All Institutions

PhD Type

PhD Type

All PhD Types

Funding

Funding

All Funding


We have 148 Pharmacology / Toxicology PhD Projects, Programs & Scholarships

PhD in Continuous Manufacturing and Advanced Crystallisation

The EPSRC CMAC Future Manufacturing Research Hub is offering 13 fully-funded industry-sponsored PhD studentships for research projects in the wider area of continuous manufacturing and advanced crystallisation. Read more

PhD in Continuous Manufacturing and Advanced Crystallisation

The EPSRC CMAC Future Manufacturing Research Hub is offering 13 fully-funded industry-sponsored PhD studentships for research projects in the wider area of continuous manufacturing and advanced crystallisation. Read more

PhD in Continuous Manufacturing and Advanced Crystallisation

The EPSRC CMAC Future Manufacturing Research Hub is offering 13 fully-funded industry-sponsored PhD studentships for research projects in the wider area of continuous manufacturing and advanced crystallisation. Read more

PhD in Continuous Manufacturing and Advanced Crystallisation

The EPSRC CMAC Future Manufacturing Research Hub is offering 13 fully-funded industry-sponsored PhD studentships for research projects in the wider area of continuous manufacturing and advanced crystallisation. Read more

Biological Rhythms and Neuronal Pharmacology

We are pleased to offer the opportunity for a self-funded PhD student to join our research teams within the School of Pharmacy, University of Kent and the Department of Clinical Neurosciences, University of Oxford. Read more

Biological Rhythms and Neuronal Pharmacology

We are pleased to offer the opportunity for a self-funded PhD student to join our research teams within the School of Pharmacy, University of Kent and the Department of Clinical Neurosciences, University of Oxford. Read more

Formulation of layered silicate-polymer composite particles for the potential oral delivery of biologics

Oral administration for pharmaceutical actives is the most convenient and preferred method of drug administration but it is challenging to develop oral delivery systems for biologics such as recombinant proteins, peptides, and vaccines. Read more

Formulation of layered silicate-polymer composite particles for the potential oral delivery of biologics

Oral administration for pharmaceutical actives is the most convenient and preferred method of drug administration but it is challenging to develop oral delivery systems for biologics such as recombinant proteins, peptides, and vaccines. Read more

Anti-Viral Plastic Antibodies for Diagnostics and Therapeutics

The need to quickly generate new diagnostic tools and therapies in the battle against viral diseases has been highlighted recently by the continuing global pandemic caused by the SARS-CoV-2 virus. Read more

Anti-Viral Plastic Antibodies for Diagnostics and Therapeutics

The need to quickly generate new diagnostic tools and therapies in the battle against viral diseases has been highlighted recently by the continuing global pandemic caused by the SARS-CoV-2 virus. Read more

Re-purposing diabetes medicines to manage bleeding complications in myeloproliferative neoplasms.

Myeloproliferative neoplasms (MPNs) are a group of three related blood cancers in which the bone marrow overproduces one of the three cellular components of blood (erythrocytes, leukocytes and platelets). Read more

Modulation of platelet-mediated innate immune responses in chronic lymphocytic leukaemia

Chronic lymphocytic leukaemia (CLL) is the most common form of leukaemia in the Western World. B-cell receptor-induced intracellular signals are critical for the survival of leukaemia cells and disruption of this pathway by the Bruton’s tyrosine kinase (Btk) inhibitor ibrutinib is a highly effective CLL therapy. Read more

Filtering Results